Lawrence phillip Goldstick , MD

MD: Michigan State University East Lansing, ML, 1979

Special Fellowship: Cleveland Clinic Foundation Cleveland, OH, 1986 (Electroencephalography, Epilepsy, Evoked Potentials and Clinical Neurophysiology )

Residency: University of Cincinnati 1984

Undergrad: University of Michigan 1975

American Board of Psychiatry and Neurology (Neurology) (Certification Date: 06-30-1986 )

Neurology

Aicardi Syndrome

Autoimmune Encephalitis

Behcet Syndrome (Neuro-Bechet)

Demyelinating Autoimmune Diseases, CNS

Demyelinating Disease

Devic's disease (Neuromyelitis optica)

Encephalitis

Encephalomyelitis

Limbic Encephalitis

Meningioma

Multiple Sclerosis (MS)

Myelin-Oligodendrocyte Glycoprotein

Myelitis

Neuromyelitis Optica Spectrucm Disorder (NMOSD)

Paraneoplastic Syndromes of the Nervous System

Primary Progressive Multiple Sclerosis (PPMS)

Relapsing-Remitting Multiple Sclerosis

Sarcoidosis (Neurosarcoidosis)

Secondary Progressive Multiple Sclerosis (SPMS)

Sjogrens Syndrome (Neuro-Sjogren)

Susac Syndrome

Systemic Lupus Syndrome (CNS-Lupus)

Transverse Myelitis

Neurology

MS Specialist

Grant: #UOC-213425 / PCORI PSC-1504-30133 Investigators:Goldstick, Lawrence; Martin, Vincent 05-01-2016 -04-30-2021 Patient-Centered Outcomes Research Institute Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication Overuse Role:Collaborator $212,364.09 Active Level:Private Non-Profit

Grant: #MS-1610-37115 Investigators:Dragan, Elizabeth; Goldstick, Lawrence 04-12-2018 -02-01-2024 Patient-Centered Outcomes Research Institute TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial Role:Collaborator $41,824.70 Awarded Level:Private Non-Profit

Investigators:Goldstick, Lawrence 12-07-2021 -12-06-2026 Genentech, Inc. A MULTIPLE-CENTER, NON-RANDOMIZED, OPEN-LABEL, ADAPTIVE, SINGLE ASCENDING DOSE, PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7 Role:PI 417773.11 Hold Level:Industry

Grant: #CN42097 Investigators:Goldstick, Lawrence 02-21-2022 -02-20-2025 Genentech, Inc. A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUTANE Role:PI 644128.40 Hold Level:Industry

Grant: #EFC17504 12-18-2023 -12-28-2026 Sanofi US Services Inc. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis Role:PI 1188400.66 Hold Level:Industry

Grant: #EFC17504 12-18-2023 -12-28-2026 Sanofi US Services Inc. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis Role:PI 1188400.66 Hold Level:Industry

12-20-2023 -12-20-2026 IQVIA Clinical Trial Payments A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (less50 years) Treated with Cladribine T Role:PI 66786.01 Hold Level:Industry

12-20-2023 -12-20-2026 IQVIA Clinical Trial Payments A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (less50 years) Treated with Cladribine T Role:PI 66786.01 Hold Level:Industry

Grant: #WO_2023_024384 12-18-2023 -12-31-2026 Sanofi US Services Inc. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Fo Role:PI 858263.71 Hold Level:Industry

Grant: #WO_2023_024384 12-18-2023 -12-31-2026 Sanofi US Services Inc. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Fo Role:PI 858263.71 Hold Level:Industry

Grant: #257MS201 03-04-2024 -03-26-2027 IQVIA Clinical Trial Payments A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and Combination Therapy w/ Diroximel Fumar Role:PI 257443.03 Hold Level:Industry

Grant: #257MS201 03-04-2024 -03-26-2027 IQVIA Clinical Trial Payments A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and Combination Therapy w/ Diroximel Fumar Role:PI 257443.03 Hold Level:Industry

Grant: #Hercules LTS Investigators:Goldstick, Lawrence 02-17-2024 -02-16-2025 IQVIA Clinical Trial Payments An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, o Role:PI 394529.30 Hold Level:Industry

Grant: #TG1101-RMS401 05-28-2024 -05-28-2027 TG Therapeutics, Inc. Title Evaluating efficacy when transitioning from a current Disease Modifying Therapy (DMT) to ublituximab (ENHANCE) Abstract The development of B-cell depleting therapies in MS was prompted by physic Role:PI 83887.99 Hold Level:Industry

Grant: #TG1101-RMS401 05-28-2024 -05-28-2027 TG Therapeutics, Inc. Title Evaluating efficacy when transitioning from a current Disease Modifying Therapy (DMT) to ublituximab (ENHANCE) Abstract The development of B-cell depleting therapies in MS was prompted by physic Role:PI 83887.99 Hold Level:Industry